- Home
- XMTR vs TNGX Comparison
XMTR vs TNGX Comparison
Compare XMTR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XMTR | TNGX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XMTR | TNGX |
|---|---|---|
| Price | $89.86 | $25.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $58.60 | $21.78 |
| AVG Volume (30 Days) | 734.1K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | $62,384,000.00 |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.87 | ★ 48.29 |
| 52 Week Low | $35.86 | $6.25 |
| 52 Week High | $106.08 | $34.39 |
Technical Indicators
Market Signals| Indicator | XMTR | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 41.97 |
| Support Level | $88.52 | $25.33 |
| Resistance Level | $98.55 | $25.76 |
| Average True Range (ATR) | 4.56 | 1.51 |
| MACD | 0.42 | -0.24 |
| Stochastic Oscillator | 56.12 | 16.50 |
Price Performance
Historical ComparisonAbout XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.